A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
News|Articles|December 10, 2014
Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers
Key Takeaways
- Immunotherapy advancements in hematological cancers, especially Hodgkin lymphoma, show promising potential for treatment improvements.
- The American Society of Hematology's annual meeting highlighted significant progress in blood cancer research.
Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.
Advertisement
Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies. The latest in blood cancer research, including studies involving immunotherapy for Hodgkin lymphoma, were announced at the annual meeting of the American Society of Hematology.
Advertisement
Related to this article
Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.
Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.
Some patients with lymphoma show no detectable cancer by day 8 of treatment, and a lymphoma specialist explains how early testing could guide care.
She was diagnosed with stage 4 primary mediastinal B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma that starts in the center of the chest, at 29.
For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.
Bern Pollock uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
A metastatic breast cancer survivor shares how exercise gave her a sense of control while emphasizing why it should never be used to blame people with cancer.
Advertisement
Advertisement
Trending on CURE
1
Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer
2
Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free
3
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
4
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
5